Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $135.0833.

A number of research analysts recently commented on the stock. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Piper Sandler restated an “overweight” rating and set a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Barclays initiated coverage on Abivax in a report on Monday, October 13th. They issued an “overweight” rating and a $142.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Finally, Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th.

Hedge Funds Weigh In On Abivax

A number of large investors have recently bought and sold shares of ABVX. TCG Crossover Management LLC raised its holdings in shares of Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares in the last quarter. UBS Group AG boosted its stake in shares of Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. purchased a new position in Abivax during the third quarter valued at approximately $263,698,000. Paradigm Biocapital Advisors LP bought a new position in Abivax in the third quarter worth approximately $132,800,000. Finally, Octagon Capital Advisors LP lifted its holdings in Abivax by 3.0% during the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock worth $9,693,000 after buying an additional 37,000 shares during the period. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Trading Up 6.3%

Shares of Abivax stock opened at $117.67 on Friday. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $122.06 and a 200-day moving average price of $100.30. The firm has a market cap of $9.23 billion, a price-to-earnings ratio of -28.15 and a beta of 0.79.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. Equities research analysts anticipate that Abivax will post -2.83 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.